<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735198</url>
  </required_header>
  <id_info>
    <org_study_id>PR348/20</org_study_id>
    <nct_id>NCT04735198</nct_id>
  </id_info>
  <brief_title>Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.</brief_title>
  <acronym>TNE-IDC-COLE</acronym>
  <official_title>Effectiveness of Prophylactic Cholecystectomy in Patients With Midgut Neuroendocrine Tumor (Jejunum, Ileum or Proximal Colon) Who Require Primary Tumor Surgery. Randomized, Proof of Concept Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to study the effectiveness of prophylactic cholecystectomy in patients&#xD;
      with midgut neuroendocrine tumor (jejunum, ileum or proximal colon) who require primary tumor&#xD;
      surgery. When patients are diagnosed and are tributary to surgical treatment, the tumor might&#xD;
      compromise vascularization, and patients need an extensive bowel resection. The patients&#xD;
      might also receive medical treatment with somatostatin analogs. The combination of extensive&#xD;
      bowel resection and medical treatment might increase gallbladder stones, but patients might&#xD;
      not develop biliary stone disease, as in the general population, where 20% of the population&#xD;
      have gallbladder stones but only a 10 to 15 % of the population will develop symptoms.&#xD;
&#xD;
      The idea comes from the lack of literature about the incidence of biliary Stone disease in&#xD;
      patients with midgut NET tumors.&#xD;
&#xD;
      It's a multicentric, open-label and randomized clinical trial to evaluate the incidence of&#xD;
      biliary stone disease in patients with midgut NET who require primary tumor surgery combined&#xD;
      or not to cholecystectomy.&#xD;
&#xD;
      Our hypothesis suggests that patients with midgut neuroendocrine tumor who require primary&#xD;
      tumor resection without the combination of prophylactic cholecystectomy do not have an&#xD;
      increased incidence of biliary stone disease two years after the surgery, regardless of&#xD;
      treatment with SSA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Effectiveness of prophylactic cholecystectomy in patients with midgut neuroendocrine&#xD;
      tumor (jejunum, ileum or proximal colon) who require primary tumor surgery. Randomized, proof&#xD;
      of concept clinical trial.&#xD;
&#xD;
      Background: The prevalence of midgut NET has increased due to advances in diagnostic tests&#xD;
      and its indolent course. When patients are diagnosed, they might be tributary to surgical&#xD;
      treatment requiring an extensive bowel resection, and medical treatment with somatostatin&#xD;
      analogs. Both treatments are related with gallbladder stone formation. The ENETS and NANETs&#xD;
      recommend prophylactic cholecystectomy in patients with midgut NET who require primary tumor&#xD;
      surgery, However, there is a lack of scientific evidence reinforcing this recommendation.&#xD;
&#xD;
      Objectives: The main objective is to evaluate the cumulated incidence rate of biliary stone&#xD;
      disease in patients with midgut NET who require primary tumor resection, two years after the&#xD;
      surgery.&#xD;
&#xD;
      Design: It's a multicentric, open-label and randomized clinical trial. Patients will be&#xD;
      recruited from the General Surgery Services of the six Hospitals participating in the study.&#xD;
      Patients must fullfill inclusion and exclusion criteria.&#xD;
&#xD;
      It is expected to recruit a maximum of one hundred patients in two years (50 per group).&#xD;
      Patients will be randomly assigned into the Experimental group (primary tumor resections) or&#xD;
      Control group (primary tumor resections combined with cholecystectomy). The investigators&#xD;
      will follow up patients until week 104 after surgery (8 visits).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the rate of biliary stone disease associated to patients with midgut NET that have gone through primary tumor surgery.</measure>
    <time_frame>Two years after the surgery</time_frame>
    <description>Incidence of biliary stone disease in patients with midgut NET who requiere primary tumor surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence of post-operative complications until day 28 +/- 3 (1 Month) after the surgery.</measure>
    <time_frame>One month after the surgery</time_frame>
    <description>Postoperative complications according Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence of: anastomotic dehiscence, wound infection, reoperation.</measure>
    <time_frame>One month after the surgery</time_frame>
    <description>Specific complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of gallstone in patients who require a bowel resection and/or ileocecal junction resection.</measure>
    <time_frame>Two years after the surgery</time_frame>
    <description>choledochal lithiasis or cholelithiasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate de incidence of gallstones in patients who will receive medical treatment with SSA</measure>
    <time_frame>Two years after the surgery</time_frame>
    <description>choledochal lithiasis or cholelithiasis according medical treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe bowel movements of patients after the surgery.</measure>
    <time_frame>Two years after the surgery</time_frame>
    <description>Gastrointestinal Quality of Life Index (GIQLY);Minimum value of 0 (the worst health state) and a maximum of 100 (best health state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare quality of life in patients who went through a prophylactic cholecystectomy against those who did not.</measure>
    <time_frame>Two years after the surgery</time_frame>
    <description>Health related Quality of life 15 D (HRQoL 15D);There are 15 areas with a minimum value of 0 (the worst health state) and a maximum of 100 (best health state) 15D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Midgut Carcinoid Tumor</condition>
  <condition>Biliary Stones</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with midgut neuroendocrine tumor who will undergo only primary tumor surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with midgut neuroendocrine tumor that will undergo through primary tumor surgery combined with prophylactic cholecystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary tumor surgery</intervention_name>
    <description>Large bowel resection.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Bowel resection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy</intervention_name>
    <description>Large bowel resection combined and cholecystectomy.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>prophylactic cholecystectomy.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must grant the informed consent written, signed and dated.&#xD;
&#xD;
          -  Male or female older than 18 years old.&#xD;
&#xD;
          -  Radiological or histological diagnose of midgut NET that can be treated with surgery.&#xD;
&#xD;
          -  In case of female with childbearing age (time between menarche and menopause), a&#xD;
             pregnancy test with negative result.&#xD;
&#xD;
          -  Neuroendocrine tumors located in any of the aforementioned locations.&#xD;
&#xD;
          -  Presence or not of distant metastasis.&#xD;
&#xD;
          -  Presencié or not of gallstones.&#xD;
&#xD;
          -  Capacity of follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neuroendocrine tumors which are not located in jejunum or ileum (bronchial, gastric,&#xD;
             pancreatic, descending colon, sigma or rectum.).&#xD;
&#xD;
          -  Patients that have gone through a previous bowel resection.&#xD;
&#xD;
          -  Patients with previous cholecystectomy.&#xD;
&#xD;
          -  Pacients with biliary stone disease.&#xD;
&#xD;
          -  Patients who are candidate to liver resection or liver transplant.&#xD;
&#xD;
          -  Patients with a gallbladder polyp bigger than 6 mm.&#xD;
&#xD;
          -  Pacients with one gallbladder sessile polyp, presence of more than one polyp or&#xD;
             patients older than 50 years old with a polyp.&#xD;
&#xD;
          -  Refusal to participate.&#xD;
&#xD;
          -  Patients with previous history of malignant neoplasms in the last 5 years, except skin&#xD;
             basal cell carcinoma, &quot;in situ&quot; cervical carcinoma or in situ carcinoma found in a&#xD;
             polyp removed with a colonoscopy.&#xD;
&#xD;
          -  Medical criteria that doesn't consider the patient a candidate to participate in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Frago Montanuy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inés Ginot</last_name>
    <phone>696014147</phone>
    <email>inesginot@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Vela</last_name>
      <email>sandravela1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IDIBELL, Hospital Universitari de Bellvitge.</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inés Ginot</last_name>
      <phone>696014147</phone>
      <email>inesginot@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan Altet</last_name>
      <email>joanaltet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joan Altet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Luís Sánchez</last_name>
      <email>30208jsg@comb.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luís Miguel Jiménez</last_name>
      <email>luismijg@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Ricardo Frago Montanuy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Neuroendocrine tumor</keyword>
  <keyword>prophylactic cholecystectomy</keyword>
  <keyword>Biliary stone disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Cholelithiasis</mesh_term>
    <mesh_term>Cholecystolithiasis</mesh_term>
    <mesh_term>Gallstones</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>That's not decided yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

